Abstract: A speaker includes a frame, a vibration assembly and a magnetic circuit assembly. The vibration assembly is assembled on the frame. The magnetic circuit assembly is assembled on the frame. The vibration assembly includes a voice coil and a piezoelectric element, the voice coil and the piezoelectric element are arranged coaxially, and the voice coil is between the piezoelectric element and the magnetic circuit assembly.

Abstract: Disclosed is an antigen-targeting, anti-CD16A and immune effector cell-activating trifunctional fusion protein, which comprises a CD16A binding region that specifically binds to CD16A, a TAA binding region that specifically binds to a tumor-associated antigen (TAA), an IL-15/IL-15 R? complex formed by means of binding of IL-15 to IL-15 R?, and an FC domain. The designed tumor-targeting innate immune cell activating molecule, i.e. the anti-TAA, anti-CD 16A and cytokine IL15 trifunctional fusion protein, can simultaneously bind to a TAA on a tumor cell and CD16A on an NK cell, thereby making the NK cell target tumors. The NK cell releases perforin and granzyme to induce apoptosis and cause the death of the tumor cells. The cytokine IL 15 is expanded to maintain the function of the NK cell, stimulate the proliferation of immune cells, and change the immune microenviroument of the tumor.

Abstract: Provided are an anti-CD3 antibody variant, a fusion protein, and an application. An anti-CD3 antibody is mutated to obtain a variant thereof. The provided fusion protein comprises: (1) an anti-tumor-associated antigen (TAA)/anti-CD3 bispecific antibody; (2) anti-TAA, anti-CD3 and IL15/IL15Ra-containing multifunctional fusion proteins; and (3) anti-TAA and IL15/IL15Ra-containing fusion proteins. Further provided are a nucleic acid molecule encoding an antibody molecule and a vector, and a pharmaceutical use of the antibody molecule.

Abstract: The embodiment of the present disclosure provides a welding device, a welding method, and an installation and debugging method thereof. The welding device includes a baseboard, comprising: a left welding nozzle and a right welding nozzle, a power shaft, a bidirectional moving wheel, and two welding nozzle connecting shafts, wherein the welding nozzle connecting shafts are connected to the left welding nozzle and the right welding nozzle respectively, and the bidirectional moving wheel which is driven by the power shaft drives the two welding nozzle connecting shafts to move towards or away from each other.

Abstract: An anti-SIRP? antibody or an antigen-binding fragment thereof, and use thereof are provided. The anti-human SIRP? monoclonal antibody is obtained by means of immunizing mice, and a chimeric antibody and a humanized antibody are further obtained. The provided anti-SIRP? antibody or antigen-binding fragment thereof can bind to the human SIRP? protein, block the CD47-SIRP? signaling pathway, and have immune regulation effects such as enhancing phagocytosis. Further provided are a pharmaceutical composition and a nucleic acid molecule, and the use of the anti-SIRP? antibody or the antigen-binding fragment thereof in the preparation of a drug for inhibiting or treating diseases.

Abstract: The embodiment of the present disclosure provides a welding device, a welding method, and an installation and debugging method thereof. The welding device includes a baseboard, comprising: a left welding nozzle and a right welding nozzle, a power shaft, a bidirectional moving wheel, and two welding nozzle connecting shafts, wherein the welding nozzle connecting shafts are connected to the left welding nozzle and the right welding nozzle respectively, and the bidirectional moving wheel which is driven by the power shaft drives the two welding nozzle connecting shafts to move towards or away from each other.

Abstract: The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

Abstract: A bispecific antibody targeting human claudin and human PDL1 proteins, containing an anti-human claudin18.2 antibody moiety and an anti-PD-L1 antibody moiety. The bispecific antibody can not only bind to human claudin18.2 protein, but also block binding of PD-1/PD-L1, and can not only activate NK cells and kill tumor cells in the innate immunity, but also promote the killing effect of killer T lymphocytes on tumors in the acquired immunity. The bispecific antibody has better anti-tumor efficacy than an anti-claudin18.2 antibody alone.

Abstract: Provided are an anti-PD-L1 nanobody and an Fc fusion protein thereof, and an application thereof. The anti-PD-L1 nanobody and the Fc fusion protein thereof have strong specificity, high affinity, and weak immunogenicity to humans. In addition, same have high stability and a significant anti-tumor effect.

Abstract: Provided are an anti-CLDN18.2 antibody and a pharmaceutical composition thereof and a detection method therefor, wherein the heavy chain of the antibody is selected from any one of SEQ ID NOs: 1-7 or SEQ ID NOs: 15-30, and the light chain of the antibody is selected from any one of SEQ ID NOs: 8-14 or SEQ ID NOs: 31-46. The ability of the antibody to bind to cell lines and tumor tissue cells is more powerful than that of the existing antibody IMAB362, and the anti-tumor effect of the antibody is also more powerful than that of the existing antibody IMAB362.

Abstract: The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

Abstract: The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

Abstract: A method is presented for controlling process delay times between a) thin film deposition and lubricant application, and b) lubricant application and abrasive polishing. Applicants have discovered that for certain lubricants, a minimum delay time after the overcoat has been deposited before the lubricant is applied increases the number of disks passing the glide test after abrasive polishing. In addition, applicants have discovered that for certain lubricants, the abrasive polishing should take place within a maximum time window following the application of the lubricant. A computerized work-in-progress tracking system is preferably used to implement the method of the invention.

Abstract: A method is presented for controlling process delay times between a) thin film deposition and lubricant application, and b) lubricant application and abrasive polishing. Applicants have discovered that for certain lubricants, a minimum delay time after the overcoat has been deposited before the lubricant is applied increases the number of disks passing the glide test after abrasive polishing. In addition, applicants have discovered that for certain lubricants, the abrasive polishing should take place within a maximum time window following the application of the lubricant. A computerized work-in-progress tracking system is preferably used to implement the method of the invention.